Ozempic And Wegovy
- All
- News
-
Tanmay Bhat Says He Had No Hunger Suppression While On Weight Loss Drugs; Here's Why
While GLP-1 medications are highly effective for many, an estimated 13% to 25% of users may be considered non-responders who do not experience desired appetite suppression or weight loss.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Ozempic Injection Price In India: How Affordable Is It For Diabetes And Weight Loss?
Ozempic, a once-weekly semaglutide injection for type-2 diabetes, has debuted in India with pricing starting at roughly Rs 2,200 per week.
-
Ozempic Launched In India: Doctors Welcome New Diabetes Drug, Warn Against Misuse For Weight Loss
Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.
-
"Unusual" Side Effect of Ozempic-Like Drugs Challenges Doctors: Research
GLP-1 medications, Ozempic and Wegovy, may disrupt cancer imaging and its diagnosis, new research has revealed.
-
Tanmay Bhat Says He Had No Hunger Suppression While On Weight Loss Drugs; Here's Why
While GLP-1 medications are highly effective for many, an estimated 13% to 25% of users may be considered non-responders who do not experience desired appetite suppression or weight loss.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Ozempic Injection Price In India: How Affordable Is It For Diabetes And Weight Loss?
Ozempic, a once-weekly semaglutide injection for type-2 diabetes, has debuted in India with pricing starting at roughly Rs 2,200 per week.
-
Ozempic Launched In India: Doctors Welcome New Diabetes Drug, Warn Against Misuse For Weight Loss
Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.
-
"Unusual" Side Effect of Ozempic-Like Drugs Challenges Doctors: Research
GLP-1 medications, Ozempic and Wegovy, may disrupt cancer imaging and its diagnosis, new research has revealed.
